EC approves Ipsen's Xermelo for carcinoid syndrome diarrhea

The European Commission approved Xermelo telotristat ethyl (LX1032, LX1606) from Ipsen Group (Euronext:IPN; Pink:IPSEY) in September to treat carcinoid syndrome diarrhea in combination with a somatostatin analog (SSA) inadequately controlled by SSA therapy...